Weight Loss Research
Lipolysis, GH secretagogues, and adipose tissue modulation in obesity models
What Is This Category?
Weight loss peptide research centres on compounds that either directly break down fat cells or stimulate the body's own growth hormone — which drives fat burning, lean mass preservation, and metabolic health. AOD-9604 is an engineered fragment of human growth hormone designed specifically to activate fat-cell breakdown (lipolysis) without the blood sugar dysregulation or anabolic side-effects of full-length HGH. CJC-1295 and Ipamorelin are studied in combination: CJC-1295 signals the pituitary gland to produce more growth hormone, while Ipamorelin amplifies the resulting pulse — producing up to 5× more GH than either compound alone, with a highly selective profile that avoids the cortisol and prolactin increases seen with older GH-releasing peptides. Together, these compounds represent a sophisticated approach to metabolic research that goes well beyond simple calorie restriction.
What People Research This For
- →Stubborn body fat reduction, particularly visceral/abdominal fat
- →Improving body composition ratio (lean mass vs fat mass)
- →Growth hormone optimisation without exogenous HGH
- →CJC-1295 + Ipamorelin combination stack for synergistic GH secretion
- →Metabolic rate and fat oxidation research
- →Recovery and sleep quality improvement (GH pulses occur during deep sleep)
Pros & Cons
Effects Timeline
Based on published study timelines. Human extrapolation is approximate — individual results vary.
GH serum elevation from CJC-1295 is detectable within 24 hours of first injection. Measurable body composition changes (DXA-measured fat mass reduction) in animal models require 4–6 weeks at minimum. Human self-researcher timelines are typically 8–12 weeks before significant changes in body composition become visible.
Scientific Overview
Weight loss peptide research focuses primarily on compounds that either directly promote lipolysis (fat breakdown) or stimulate growth hormone (GH) secretion, which secondarily drives fat oxidation. AOD-9604 is a modified fragment of the C-terminal portion of human growth hormone (hGH 176–191) that retains the lipolytic activity of GH without its proliferative or diabetogenic effects. CJC-1295 with DAC (Drug Affinity Complex) is a GHRH (growth hormone-releasing hormone) analogue with extended half-life due to albumin binding. Ipamorelin is a selective GH secretagogue that stimulates pulsatile GH release without the cortisol/prolactin side-effects of first-generation GHRPs.
Mechanism of Action
AOD-9604 activates β3-adrenergic receptors in adipose tissue, stimulating lipolysis via cAMP/PKA-mediated phosphorylation of hormone-sensitive lipase (HSL), without binding the IGF-1 receptor. CJC-1295 DAC binds GHRH receptors on pituitary somatotrophs, driving GH synthesis and release; DAC modification enables albumin binding that extends half-life to 6–8 days. Ipamorelin mimics ghrelin at the GHS-R1a receptor, producing selective, pulsatile GH release with minimal effect on ACTH, cortisol, or prolactin.
Administration Methods
Each peptide is reconstituted individually in bacteriostatic water. AOD-9604: 1 mg/mL; CJC-1295 DAC: 2 mg/mL; Ipamorelin: 2 mg/mL. Store at 4 °C after reconstitution.
AOD-9604: 300 µg/mL; CJC-1295: 1 mg/mL; Ipamorelin: 200 µg/mL
Ipamorelin is typically dosed immediately pre-sleep or pre-exercise in animal models. CJC-1295 DAC can be dosed weekly due to its extended half-life.
Research Protocols
Body weight (twice weekly), fat mass % (DXA or MRI), adipose tissue lipolysis (glycerol release from explants), serum lipid profile (triglycerides, FFA)
GH serum pulsatility (serial sampling every 20 min over 4 hours), IGF-1 serum (ELISA), body composition by DXA at days 0 and 28
Key Published Studies
AOD9604: An anti-obesity drug which acts on the β3-adrenoceptor
1998AOD9604 stimulated lipolysis in adipocytes exclusively via β3-adrenergic receptors without detectable IGF-1 receptor binding, demonstrating a cleaner metabolic profile than full-length hGH in DIO rat models.
Long-acting growth hormone-releasing hormone analogue (CJC-1295) stimulates growth hormone and insulin-like growth factor-I secretion
2006A single injection of CJC-1295 produced GH secretion lasting 6 days and dose-dependent increases in serum IGF-1 of 2–3×, demonstrating the utility of albumin-binding for sustained GHRH-receptor agonism.
Expected Outcomes
Based on the weight of published preclinical evidence. Outcomes may vary depending on model, dose, and administration route.
- ✓Reduced fat mass (DXA) without change in lean body mass (AOD-9604)
- ✓Increased adipocyte lipolysis (glycerol release, FFA) in ex vivo adipose assays
- ✓Elevated pulsatile GH secretion and IGF-1 (CJC-1295 + Ipamorelin combination)
- ✓No significant insulin resistance or hyperglycaemia (AOD-9604 selectivity advantage)
- ✓Improved body composition ratio (lean mass / fat mass) at 6 weeks
Safety Considerations
- ⚠AOD-9604 completed Phase III clinical trials without safety signals; FDA GRAS status was granted for oral formulation.
- ⚠CJC-1295 and Ipamorelin significantly increase GH/IGF-1; glucose monitoring is recommended in diabetic-prone animal strains.
- ⚠GH secretagogues may promote proliferation in pre-existing neoplastic lesions; tumour surveillance should be included in aged animal studies.
- ⚠Not approved for human weight loss. Research use only.
Frequently Asked Questions
Does AOD-9604 affect blood glucose like GH?
No. AOD-9604 was specifically engineered to lack the diabetogenic and anabolic effects of full-length GH. It does not bind the IGF-1 receptor or significantly alter fasting glucose in published studies, which is a key safety advantage in obesity research.
Why combine CJC-1295 with Ipamorelin rather than use either alone?
CJC-1295 (GHRH analogue) and Ipamorelin (GHS-R agonist) act via distinct receptor pathways that converge on somatotroph GH release. Their combination produces synergistic GH secretion (2–5× AUC vs. monotherapy) while Ipamorelin's selectivity keeps cortisol and prolactin elevations minimal.
Practical Notes for Self-Researchers
When is the best time to inject CJC-1295 + Ipamorelin?
Published animal studies and the CJC-1295 Phase I trial use a single weekly or biweekly SC injection without time-of-day specification. The self-research community commonly doses Ipamorelin immediately before sleep, as natural GH secretion is highest during slow-wave sleep — and GH secretagogues amplify this natural pulse. CJC-1295 DAC is typically injected once weekly at any time due to its extended half-life.
Is AOD-9604 a safer alternative to HGH for fat loss?
AOD-9604 was specifically engineered to retain the lipolytic (fat-burning) activity of growth hormone while eliminating its anabolic and diabetogenic effects. It does not bind the IGF-1 receptor and does not significantly alter blood glucose in published studies — key advantages over full-length HGH. However, "safer" must be understood in context: AOD-9604 has no long-term human safety data for injectable use, and the FDA GRAS designation applies to an oral formulation, not injectable.
Do I need to cycle off CJC-1295 and Ipamorelin?
Published human trials ran for 4–6 weeks without tolerance or desensitisation issues. The self-research community commonly uses 3-month on / 1-month off cycles, though this is convention rather than evidence-based protocol. There is theoretical concern that chronic GHRH receptor stimulation could cause pituitary desensitisation over very long periods — a risk that has not been systematically studied at research peptide doses.
Source Peptides for Your Research
Compare Africa-accessible peptide vendors on purity, testing, Africa shipping, and price per mg.